We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply.
DNA methylation performs an essential function in mammalian ontogeny. It is also known that abnormalities in this process cause the development of cancers such as leukemia.
Activating the immune system of the body is a promising form of treatment for cancer. Researchers at the University of Helsinki and Helsinki University Hospital as well as the University of Eastern Finland mapped out the immune landscape of hematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies.
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.
Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.
Researchers at Children's Cancer Institute have discovered what could prove a new and improved way to treat the poor-prognosis blood cancer, acute myeloid leukemia or AML.
Acute myeloid leukemia is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and genetically very heterogeneous.
City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.
By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy.
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.